CytoImmune Therapeutics Welcomes Aleksey Krylov, Chief Financial Officer

LOS ANGELES: LOS ANGELES, June 24, 2021 /PRNewswire/ -- CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of natural killer (NK) cell-based cancer therapies, today announce the appointment of Aleksey Krylov as Chief Financial Officer (CFO), effective as of April 14, 2021. As the company advances human clinical...

Click to view original post